Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Atomo Diagnostics Ltd. ( (AU:AT1) ) just unveiled an update.
Atomo Diagnostics Ltd. has announced a change in the director’s interest, specifically involving John Kelly, who is a controller of Dalraida Holdings Pty Ltd. The change involved the expiry of 666,666 unquoted options without exercise as of April 14, 2025. This adjustment in the director’s interest does not involve any acquisition or disposal of shares, indicating a neutral impact on the company’s operations and market positioning.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. operates in the medical diagnostics industry, focusing on the development and commercialization of rapid diagnostic test devices. The company is known for its innovative point-of-care testing solutions, which are designed to be user-friendly and accessible, catering to both healthcare professionals and consumers.
Average Trading Volume: 442,443
Technical Sentiment Signal: Buy
Current Market Cap: A$12.78M
For detailed information about AT1 stock, go to TipRanks’ Stock Analysis page.